NASDAQ · Biotechnology

ABCL (ABCL) Stock

$11.28 -1.74% NASDAQ: ABCL Healthcare

Valuation

MetricValue
Price$11.28
Market Cap$3.44B
P/E Ratio-21.26
P/B Ratio3.91
P/S Ratio52.98
EPS (TTM)$-0.84
52-Week High$12.58
52-Week Low$2.75
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-17.49%
ROA-12.59%
ROCE-17.95%
Gross Margin89.50%
Operating Margin-2.68%
Net Margin-248.83%
Debt/Equity0.15
Current Ratio11.38

Annual Financials (USD)

Metric20212022202320242025
Revenue$375.0M$485.0M$38.0M$29.0M$75.0M
Operating Profit$204.0M$217.0M$-237.0M$-315.0M$-217.0M
Net Profit$153.0M$159.0M$-146.0M$-163.0M$-146.0M
EPS$0.48$0.50$-0.51$-0.55$-0.49
Op Margin54.5%44.6%-623.8%-1091.7%-289.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.3B$1.5B$1.5B$1.4B$1.4B
Total Liabilities$293.0M$308.0M$336.0M$304.0M$390.0M
Cash$476.0M$387.0M$133.0M$156.0M$129.0M
Borrowings$40.0M$82.0M$77.0M$65.0M$143.0M

Latest News

As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22 CNW Group · Jul 15, 2026 AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026 Business Wire · Jul 7, 2026 Are You Looking for a Top Momentum Pick? Why AbCellera Biologics Inc. (ABCL) is a Great Choice Zacks · Jul 7, 2026 Benchmark Upgrades AbCellera Biologics to Buy From Hold, Price Target is $11 MT Newswires · Jul 7, 2026 AbCellera Appoints Dr. Lynn Seely to its Board of Directors Business Wire · Jul 6, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$245.0M$277.0M$-44.0M$-109.0M$-131.0M
Investing Cash Flow$-391.0M$-425.0M$-299.0M$43.0M$45.0M
Financing Cash Flow$-8.0M$-4.0M$-1.0M$-1.0M$14.0M
Net Cash Flow$-93.0M$-86.0M$-254.0M$23.0M$-28.0M
Free Cash Flow$186.0M$205.0M$-121.0M$-187.0M$-174.0M

Valuation & Return Ratios

MetricValue
PEG Ratio39.14
EV / EBITDA-21.97
FCF Yield-5.12%
Quick Ratio12.63
Interest Coverage0.00
Return 1Y183.22%
Return 3Y124.00%
Return 5Y-29.92%

Ownership

Insiders Held23.04%
Institutions Held42.57%
Institutions Float Held55.32%
Institutional HolderSharesReport Date
Baker Bros. Advisors, LP30,275,9382026-03-31
Capital World Investors13,361,0962026-03-31
Two Sigma Investments, LP10,562,0652026-03-31
TD Waterhouse Canada Inc.9,564,6592026-03-31
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC7,575,4762026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BHVN $15.74 +3.08% -6.11 $2.37B 0.00%
CLDX $39.24 -0.98% -7.84 $2.61B 0.00%
IMNM $27.07 -1.26% -8.13 $2.59B 0.00%
JANX $18.89 +3.68% -7.78 $1.15B 0.00%
NUVB $6.64 -0.30% -8.15 $2.31B 0.00%

About ABCL

ABCL is led by CEO Carl Hansen, employs 596 people, headquartered in CA, publicly traded since 2020.

ABCL stock trades at $11.28 with a market capitalization of $3.44B. The stock is valued at a price-to-earnings (P/E) ratio of -21.26, price-to-book of 3.91, price-to-sales of 52.98. Over the past 52 weeks the stock has ranged between $2.75 and $12.58, and currently trades 10.3% below its 52-week high.

On profitability, ABCL generates a return on equity (ROE) of -17.49%, return on capital employed of -17.95%, an operating margin of -2.68%, a net profit margin of -248.83%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1159.93 +0.28% JNJ Drug Manufacturers - General $271.19 +2.01% ABBV Drug Manufacturers - General $259.99 +1.39% MRK Drug Manufacturers - General $149.94 +1.48% UNH Medical - Healthcare Plans $396.30 +1.77% NVS Drug Manufacturers - General $161.25 +6.04% AZN Drug Manufacturers - General $162.47 +0.21% AMGN Drug Manufacturers - General $438.12 +1.92% TMO Medical - Diagnostics & Research $600.50 -2.69% NVO Biotechnology $45.12 -0.46% ABT Medical - Devices $108.97 -1.26% GILD Drug Manufacturers - General $149.92 +2.45%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides